Finerenone

Generic Name
Finerenone
Brand Names
Kerendia
Drug Type
Small Molecule
Chemical Formula
C21H22N4O3
CAS Number
1050477-31-0
Unique Ingredient Identifier
DE2O63YV8R
Background

Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus. Patients with kidney di...

Indication

In the US, finerenone is indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.
...

Associated Conditions
Cardiovascular Mortality, Chronic Kidney Disease, Stage 3 (Moderate), End Stage Renal Disease (ESRD), Hospitalizations, Nonfatal Myocardial Infarction, Stage 4 Chronic Kidney Disease, Sustained creatinine renal clearance decreased
Associated Therapies
-
Clinical Trials
Related News

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i As Triple Therapy with Type 2 Diabetes and Chronic Kidney Disease

Phase 4
Recruiting
Conditions
Patients with Type 2 Diabetes
Interventions
Drug: Finerenone
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
82
Registration Number
NCT06727409
Locations
🇭🇰

3M, Diabetes and Endocrine Research Center, Hong Kong, Hong Kong

Effect of Finerenone in IgA Nephropathy

Phase 3
Not yet recruiting
Conditions
IgA Nephropathy
Interventions
Drug: Placebo
Drug: Finerenone
First Posted Date
2024-08-30
Last Posted Date
2024-08-30
Lead Sponsor
Zhejiang University
Target Recruit Count
120
Registration Number
NCT06580288

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

First Posted Date
2024-06-14
Last Posted Date
2024-06-14
Lead Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Target Recruit Count
245
Registration Number
NCT06460987
Locations
🇨🇳

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy, Yiwu, Zhejiang, China

The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism

First Posted Date
2024-04-24
Last Posted Date
2024-04-24
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
55
Registration Number
NCT06381323
Locations
🇨🇳

Department of Endocrinology, Drum Tower Hospital affiliated to Nanjing University Medical School, Nanjing, Jiangsu, China

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

Phase 4
Not yet recruiting
Conditions
Primary Aldosteronism
Interventions
Drug: Spironolactone
Drug: Finerenone
First Posted Date
2023-12-11
Last Posted Date
2023-12-11
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
150
Registration Number
NCT06164379
Locations
🇨🇳

Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

First Posted Date
2023-10-23
Last Posted Date
2024-06-28
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
10
Registration Number
NCT06094920
Locations
🇳🇱

ZorgGroep Twente, Almelo, Overijssel, Netherlands

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

First Posted Date
2023-10-13
Last Posted Date
2023-10-13
Lead Sponsor
Steno Diabetes Center Copenhagen
Target Recruit Count
2000
Registration Number
NCT06082063

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

First Posted Date
2023-09-28
Last Posted Date
2024-11-21
Lead Sponsor
The George Institute
Target Recruit Count
1000
Registration Number
NCT06058585
Locations
🇦🇺

The Canberra Hospital, Garran, Australian Capital Territory, Australia

🇦🇺

John Hunter Hospital, New Lambton Heights, New South Wales, Australia

🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

and more 10 locations

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Phase 3
Not yet recruiting
Conditions
Heart Failure
Interventions
Drug: Placebo
Drug: Finerenone
First Posted Date
2023-09-13
Last Posted Date
2024-04-17
Lead Sponsor
Colorado Prevention Center
Target Recruit Count
2600
Registration Number
NCT06033950

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Phase 3
Recruiting
Conditions
Heart Failure
Interventions
Drug: Finerenone
Drug: Empagliflozin
First Posted Date
2023-09-06
Last Posted Date
2024-07-22
Lead Sponsor
Colorado Prevention Center
Target Recruit Count
1500
Registration Number
NCT06024746
Locations
🇺🇸

Kansas City, MO Investigative Site, Kansas City, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy